Evasion of cellular senescence is required for the immortal phenotype of tumor cells. The tumor suppressor genes p16INK4A, pRb, and p53 have been implicated in the induction of cellular senescence. To identify additional genes and pathways involved in the regulation of senescence in prostate epithelial cells (PrECs), we performed serial analysis of gene expression (SAGE). The gene expression pattern of human PrECs arrested because of senescence was compared with the pattern of early passage cells arrested because of confluence. A total of 144,137 SAGE tags representing 25,645 unique mRNA species was collected and analyzed: 157 mRNAs (70 with known function) were up-regulated and 116 (65 with known function) were down-regulated significantly in senescent PrECs (P < 0.05; fold difference >2.5). The differential regulation of an exemplary set of genes during senescence was confirmed by quantitative real-time PCR in PrECs derived from three different donors. The results presented here provide the molecular basis of the characteristic changes in morphology and proliferation observed in senescent PrECs. Furthermore, the differentially expressed genes identified in this report will be instrumental in the further analysis of cellular senescence in PrECs and may lead to the identification of tumor suppressor genes and proto-oncogenes involved in the development of prostate cancer.

Mammalian somatic cells have a limited proliferative capacity when cultivated in vitro. For instance, human fibroblasts stop dividing after 50–70 population doublings and enter a terminal arrest state termed replicative senescence (1). Senescent fibroblasts are strongly enlarged and refractory to mitogen stimulation. However, they are metabolically active and survive in culture for several month. A similar limitation of proliferative capacity has been observed for most other cell types (2, 3). Replicative senescence is induced by progressive telomere shortening, which occurs during each cell division (4). Telomere erosion presumably generates a DNA damage signal, which leads to activation of p53 and subsequent transcriptional induction of the cdk3 inhibitor p21CIP1. Therefore, prevention of telomere shortening by ectopic expression of the catalytic subunit of telomerase (hTERT) is sufficient to immortalize primary cells in vitro provided they are cultivated under the appropriate conditions.

Induction of a senescence-like phenotype also occurs after aberrant mitogenic signaling and after environmental and genotoxic insults. This form of senescence has been termed cellular senescence as opposed to telomere-associated replicative senescence (5). Similar to apoptosis, cellular senescence is thought to be a mechanism of tumor suppression because it prevents the outgrowth of cells that have acquired mutations in genes rendering them cancerous (6). Consistent with this model, several tumor suppressor genes (e.g., p16) or their products (p53) are activated at the onset of cellular senescence. In addition, mice engineered to display elevated p53 activity show premature aging and a drastically decreased incidence of cancer, supporting a role of cellular senescence as a tumor suppressive mechanism relevant for the whole organism (7).

Recently, it has been shown that mammary epithelial cells have the capacity to spontaneously escape replicative senescence and enter a phase of genomic instability, which may give rise to immortal cells (8). According to calculations by Morris (9), a similar evasion of replicative senescence has to occur for the development of any epithelial cancer.

Complicating the issue, the presence of senescent fibroblasts promotes the proliferation of premalignant and malignant but not normal epithelial cells presumably by generating an altered microenvironment (10). Therefore, Krtolica et al. (10) suggested that senescence may promote carcinogenesis in aged organisms while it protects against cancer early in life.

Prostatic cancer is the most frequent malignancy in the United States and the second leading cause of cancer deaths in men today (11, 12, 13, 14). Among a variety of environmental and genetic factors favoring the development of prostatic cancer, aging is the most significant risk factor. It has been estimated that 15–30% of males over the age of 50 and as many as 80% of the males over the age of 80 harbor clinically undetected foci of prostate cancer (15). On the basis of the in vivo expression of pH 6.0 specific β-galactosidase, a marker of cellular senescence (16), it has been suggested that the accumulation of senescent prostate epithelial cells within prostatic glands might play a role in the development of prostatic diseases (17).

The characterization of senescence in epithelial cells is still in its beginning. However, a detailed characterization of senescence in epithelial cells is necessary to understand how carcinoma circumvent this program. This approach may allow to identify genes involved in the development of prostate cancer, a disease for which relatively few causal genetic events are known. Furthermore, changes in gene expression during senescence of PrECs may provide insights into the aging mechanisms of the prostate. To characterize genome-wide expression during senescence of PrECs, we used SAGE, a quantitative method developed by Velculescu et al. (18). Here, we describe differentially expressed genes identified by SAGE, which presumably represent components of pathways and mechanisms involved in the induction and maintenance of senescence. Genetic inactivation or deregulation of these genes may lead to immortalization and neoplastic transformation of PrECs.

Cell Culture.

PrECs used for SAGE were derived from a 17-year-old accident victim (Clonetics, San Diego, CA). PrECs were cultivated in PrEC growth medium (Clonetics) on collagen type I vented flasks (BioCoat; BD Falcon, Bedford, MA) according to the supplier’s instructions. PrECs were passaged at ∼70% confluence by splitting 1:3 using collagenase 1S (Sigma, Deisenhofen, Germany).

For qPCR analysis, additional PrEC samples were obtained from two prostate cancer patients (patient 1: 56 years old; patient 2: 63 years old). After radical prostatectomy, tissue wedges free of malignant cells were removed from the transition zone. These explants were minced into organoids of 1 mm3 and seeded on collagen I-coated plates in PrEC growth medium, allowing a homogeneous epithelial cell population to grow out. These cytokeratin-positive cells were passaged until senescence.

Western Blots.

Antibodies specific for p21 (clone: 6B6) were obtained from BD PharMingen (Bedford, MA). p16- (clone: C-20), p15- (clone: C-20), p53- (clone: Pab 1801), p27- (clone: C-19), or α-tubulin- (clone: TU-02) specific antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Enhanced chemiluminescence signals were detected on a Image Station 440CF (Kodak-Perkin-Elmer, Boston, MA).

MicroSAGE.

MicroSAGE was performed according to a protocol (version 1.0e) accessible online.4 We included additional purification steps of DNA intermediates after each PAGE step using Sephadex G-25 columns to ensure complete removal of contaminants. In brief, mRNA was isolated from human PrECs with the Dynabeads mRNA Direct Kit (Dynal, Smestad, Norway), and cDNA was synthesized on magnetic particles using the Superscript Choise System (Invitrogen, Groningen, the Netherlands). After cleaving the cDNA with NlaIII, linkers containing recognition sites for BsmFI were ligated to the cDNA. Linker tags were released by BsmFI digestion from the magnetic particles, ligated, and a 102-bp fragment was amplified with biotinylated primers. Ditags (∼26 bp) were released by NlaIII cleavage. Biotinylated linkers were completely removed using streptavidin-linked magnetic beads and subsequent PAGE purification. The ditags were concatenated, and concatemers of 500–800 bp were subcloned into pZERO (Invitrogen). After colony PCR, products >500 bp were sequenced using BigDye-terminator V2.0 reagents (Applied Biosystems, Lincoln, CA). Products were purified using Sephadex G-50 in filter plates (Millipore, Bedford, MA) and analyzed on an automated capillary DNA Sequencer (3700; Applied Biosystems). The results were analyzed using the SAGE2000 software provided by Dr. Ken Kinzler (Johns Hopkins University Medical School, Baltimore, MD). To exclude tags generated by sequencing errors, only tags that occurred at least twice were included in the analysis. After statistical analysis using Monte Carlo simulations, SAGE tags (P < 0.05; differential regulation >2.5-fold) were assigned to cDNAs using the Unigene database (release 03/01). Tags with multiple matches were additionally analyzed after retrieving the 11th base of the tag. Matching and position of all tags listed in Tables 1 and 2 were confirmed using the tag-to-gene-mapper function provided online.5

qPCR.

qPCR analysis was performed as described in detail by Menssen and Hermeking (19). The Light Cycler, software version 3.5.2, FastStart DNA Master SYBR Green I, and cDNA synthesis reagents were used according to the manufacturer’s instructions (Roche Applied Science, Mannheim, Germany). A total of 1 μg of RNA was reverse transcribed into cDNA. PCR efficiency of different primer pairs was determined using logarithmic dilutions of cDNA templates. After determining the slope of the reaction over a range of 20–32 cycles, PCR primer efficiency was calculated according to the equation: E = 10−1/slope. Specificity of PCR products was confirmed by melting curve analysis, gel analysis, and direct sequencing (DNA Analyzer 310; Applied Biosystems). Primer sequences and examples of qPCR raw data are available as supplemental material. qPCR determinations were normalized with primers specific for eukaryotic elongation factor 1 α-1, which was equally represented in both SAGE libraries (316:369 tags). The difference in gene expression was calculated incorporating the efficiency (E) of each primer pair according to Pfaffl (20):

Senescence of Human PrECs.

Human PrECs derived from a 17-year-old accident victim were cultivated until they ceased to proliferate (10. passage, ∼30 population doublings). During serial cultivation, the frequency of cells showing markers of senescence as cellular enlargement (Fig. 1,a) and positive staining for β-galactosidase at pH 6.0 (data not shown) increased to >90% of the population. The protein levels of the cdk inhibitor p16INK4A increased during senescence of PrECs (Fig. 1,b). Furthermore, a minor increase in the protein levels of the cdk inhibitor p15INK4B could be detected (Fig. 1,b). However, no significant changes in the protein levels of p53, its transcriptional target, the cdk inhibitor p21CIP1, and the cdk inhibitor p27KIP1 could be detected as PrECs became senescent (Fig. 1,b). qPCR allowed to detect induction of p16INK4A mRNA in senescent PrECs (Fig. 1,c). Expression of p15INK4B mRNA was induced in senescent PrECs, whereas p21CIP1 and p27KIP1 mRNA levels were not significantly altered (Fig. 1,c). The qPCR results were in accordance with the Western blot analysis shown in Fig. 1,b. Connective tissue growth factor, a gene previously found to be induced during senescence of PrECs (21), was induced as detected by qPCR (Fig. 1 c). Induction of p16INK4A and unchanged p21CIP1 expression in senescent PrECs has been reported previously (22, 23). The lack of p53/p21CIP1 activation suggests that the cessation of proliferation observed in senescent PrECs was not because of shortening of telomeres and a subsequent DNA damage-mediated cell cycle arrest.

Analysis of Senescence in PrECs Using MicroSAGE.

To acquire a comprehensive, unbiased picture of changes in gene expression during senescence, SAGE was used. With SAGE, sequence tags of 10–11 bp from the 3′-end of each transcript are isolated, concatenated, and sequenced to generate so-called SAGE libraries (18). The abundance of a specific tag in a SAGE library is proportional to the expression level of its corresponding mRNA. Because of the limited number of early passage PrECs, a protocol adapted to small amounts of mRNA was used (MicroSAGE, for details see “Materials and Methods”). A SAGE library of 72,068 tags was generated from subconfluent, terminally arrested, senescent PrECs at passage 10 and compared with a library of 72,069 tags derived from PrECs arrested because of confluence at passage 3. Both cell populations were cultivated in the presence of growth factors. A comparison of senescent to exponentially proliferating, early passage PrECs was avoided because many genes would have been differentially regulated because of the drastically different growth state and cell cycle distribution of arrested versus proliferating cells. The 144,137 SAGE tags collected in total correspond to 25,645 unique mRNA species. Using statistical analysis by Monte Carlo simulation, we determined that 273 tags showed significant differential expression (P < 0.05; fold difference >2.5). The complete set of SAGE data can be accessed online.6 This web site allows the analysis and comparison of the differentially expressed tags/genes identified here with numerous other SAGE studies (24).

Confirmation of SAGE Results by qPCR.

To estimate the accuracy of the MicroSAGE analysis and to determine whether differential regulation of the identified transcripts occurs generally during senescence, qPCR was used to determine the abundance of exemplary transcripts in PrECs from three different donors (Fig. 2): differential regulation during senescence as detected by MicroSAGE was confirmed for all genes tested and is discussed in detail below. Therefore, the MicroSAGE results accurately reflect the levels of gene expression in the two cell populations analyzed. Furthermore, the changes in gene expression observed by SAGE in the senescent PrECs from one donor were also observed in senescent PrECs from two additional donors (Fig. 2). These results suggest that most of the changes in gene expression detected by SAGE in this study generally occur in senescent human PrECs.

Classification of Senescence-specific Changes in Gene Expression.

Differentially expressed SAGE tags were matched to the cDNAs of the Unigene database (release 03/01). Those transcripts, which corresponded to known genes and unambiguously contained the SAGE tag next to the most 3′ NlaIII-site, were sorted according to their function (Tables 1 and 2). Seventy genes induced in senescent PrECs are listed in Table 1, whereas 65 genes repressed during senescence are depicted in Table 2. Of the 157 tags significantly induced during senescence, 87 tags matched to functionally uncharacterized transcripts or had no matches in the database. Among the 116 repressed tags were 51 tags that had no functional assignment or matches in the database.

Because we reasoned that transcripts up-regulated during senescence may be targets for down-regulation during tumor progression (and vice versa), the expression data were compared with previously published studies or public SAGE data analyzing differential gene expression in prostate cancer (Refs. 25, 26; Tables 1 and 2, right column). For a number of genes, e.g., DKK3, the proposed correlation could be confirmed. These interesting cases are discussed below.

We also compared the SAGE results obtained here with other profiling studies on senescence performed with PrECs (27), human diploid fibroblasts (28, 29), and muscle cells (30). Indeed, we identified several examples where similar senescence-specific gene expression could be found (Tables 1 and 2, right column): e.g., PAI-1 appears as a gene universally up-regulated during senescence in different cell types (Table 1). However, most of the changes detected here are specific for PrECs (Tables 1 and 2). The tag for β-galactosidase (TTACTTTTTT, Hs. 79222) was not significantly differentially regulated (8:13 tags), which is consistent with the hypothesis that an increase in lysosomal mass is responsible for the increase in β-galactosidase activity observed in senescent cells.

Cell Cycle Regulation.

Irreversible cell cycle arrest in the presence of otherwise mitogenic growth factors is a hallmark of senescence. The changes in gene expression we detected by MicroSAGE suggest the involvement of several key regulators in the establishment and maintenance of cell cycle arrest in senescent PrECs (Tables 1 and 2). It has been shown previously that ectopic expression of the helix-loop-helix factor Id1 is able to reactivate the cell cycle in senescent human fibroblasts (31), presumably by inhibitory association with ets transcription factors, which are required for elevated expression of p16INK4A(32). A similar mechanism may be operating in PrECs: in early passage PrECs, Id1 was expressed at high levels (Table 2). However, during senescence, Id1 decreased dramatically, which may explain the induction of p16INK4A mRNA and protein (Fig. 1, b and c). Elevated p16INK4A may then lead to a reduction of G1 phase-specific cdk activity and hypophosphorylation of pRb. Active pRb binds and inactivates members of the mitogenic E2F transcription factor family, which subsequently leads to inhibition of G1-S cell cycle progression (reviewed in Ref. 33). In addition to this mode of E2F inactivation, we observed a decreased expression of E2F4 (Table 2), which may additionally contribute to the inability of senescent PrECs to traverse the G1-S phase. E2F4 is expressed at elevated levels in immortal prostate cancer cells (25), suggesting that E2F4 may be involved in immortalization of PrECs. The reduced levels of CKS-1 expression in senescent PrECs may also contribute to the permanent cell cycle arrest observed in senescent PrECs (Fig. 2,B). CKS-1 knockout mice have a profound defect in cell proliferation, suggesting that CKS-1 is necessary for full activity of Cdk2 (34). CKS proteins affect cdk activity by directly binding to cdk complexes and facilitating ubiquitin-mediated proteolysis of associated inhibitors like p27KIP1(34). However, the levels of p27KIP1 protein do not increase significantly during senescence of PrECs (Fig. 1,b). Therefore, it is likely that CKS-1 targets other proteins for degradation in early passage PrECs. Down-regulation of cyclin B1 expression was confirmed by qPCR (Fig. 2 B) and may lead to a cell cycle arrest in the G2 phase. Consistent with this observation, cell cycle arrest of senescent cells is not restricted to arrest in the G1 phase but also occurs in the G2 phase (28). Paradoxically, expression of cyclin D1 was increased in terminally arrested prostate cells. Senescent human fibroblasts show a similar increase in cyclin D1 mRNA and protein levels (35).7 This may constitute a compensatory up-regulation, which results from inhibition of the cdk4/cyclin D1 pathway by p16INK4A.

Extracellular Matrix.

Elevated levels of enzymes involved in remodeling of the ECM has been observed previously during senescence of fibroblasts (28, 29). The deregulation of these genes during senescence may contribute to the altered ECM observed in aged tissues. In senescent PrECs, elevated levels of matrix metalloproteinase MMP-14 and cathepsin B expression were detected by SAGE (Table 1). On the other hand, PAI-1, an inhibitor of a matrix-degrading protease, was induced significantly (confirmed by qPCR, Fig. 2,A). Up-regulation of PAI-1 has also been observed in other cell types undergoing senescence and presumably leads to disruption of ECM maintenance (36). Expression of the gene encoding the adhesion molecule fibronectin 1, which contains multiple binding sites for diverse ECM and cell surface molecules, was increased in senescent PrECs (confirmed by qPCR, Fig. 2,A). Consistent with an antiproliferative role of fibronectin, its expression is generally reduced in transformed cells (37). Senescent PrECs showed increased expression of β4 integrin, a transmembrane receptor, which mediates cell-matrix interactions (confirmed by qPCR, Fig. 2,A, Table 1). Down-regulation of β4 integrin is characteristic for prostate cancer and prostatic intraepithelial neoplasia (38).

Cell Shape and Motility.

Senescent PrECs undergo dramatic changes in size and shape (Fig. 1,a). These changes could be because of the up-regulation of several key regulators and components of the cytoskeleton (Table 1): e.g., the gene encoding the intermediate filament forming protein vimentin was induced in senescent PrECs (Table 1). Senescent human fibroblasts also show elevated expression of vimentin(39). In addition, the elevated expression of gelsolin (confirmed by qPCR, Fig. 2,A), which fragments actin networks in a calcium-regulated manner, may be involved in the altered morphology of senescent cells. Interestingly, levels of gelsolin are diminished in breast cancer (40) and ectopic expression of gelsolin suppresses tumorigenicity (41). Expression of intermediate chain I of cytoplasmatic dynein (DNClI) was increased in senescent PrECs. Among several components of cytoplasmic dynein, up-regulation during senescence was shown to be unique for DNClI(42). The expression of tropomyosin 1-α (confirmed by qPCR, Fig. 2,A) and fibulin-1 was increased in senescent PrECs. Interestingly, down-regulation of human epithelial tropomyosin has been observed in prostate carcinoma cells (43), and ectopic fibulin-1 expression inhibits motility and invasion of human ovarian and breast cancer cells (44). RAC1 and cdc42, which both encode GTP-binding, ras-like molecules, were induced in senescent PrECs and have been implicated in the reorganization of actin filaments during wound healing processes in fibroblasts: cdc42 expression is sufficient to induce filopodia, whereas RAC1 is required for lamellipodia formation (45). The induction of both genes is presumably involved in the characteristic spreading of senescent PrECs (Fig. 1 a).

Transcription.

As discussed above, transcription factors like Id1 and E2F4 may have central roles in regulating or antagonizing cellular events, which are part of the senescence program. The transcription factor EGR1 is the product of an immediate early growth-response gene and directly induces TGF-β expression (46). Consistent with our finding that EGR1 is repressed in senescent PrECs, expression of TGF-β is diminished concomitantly (Table 2). The transcriptional repressor ATF4 (CREB2) was repressed, suggesting that genes regulated via cyclic AMP-response elements may be derepressed during senescence of PrECs. p8, which encodes a basic-helix-loop-helix transcription factor, was significantly repressed in senescent PrECs. Interestingly, mitogenic and metastatic potential has been assigned to p8(47, 48). SKI-interacting protein (49), which was induced in senescent PrECs, functions as an antagonist of the oncogene product SKI, thereby presumably contributing to the terminal arrest of PrECs.

Signaling Molecules and Growth Factors.

Senescent PrECs are refractory to stimulation of proliferation by external growth factors, implying that repression of receptors or mediators of signaling events should be detectable. However, of the detected changes in mRNA levels only the repression of PDGFα fulfills this criterion. On the other hand, induction of negative regulators of signaling could lead to the unresponsiveness of senescent cells to mitogens: we observed induction of DKK3 (confirmed by qPCR, Fig. 2 A), which presumably represents an antagonist of wnt-signaling. Up-regulation of DKK3 during senescence was also observed in human diploid fibroblasts.7 Ectopic expression of DKK3 inhibits tumor cell proliferation and expression of DKK3 is significantly down-regulated in non-small cell lung carcinomas (50). Interestingly, DKK3 is localized on 11p15, a locus often deleted in human cancer (50).

IFNs are capable of generating a variety of cellular responses, e.g., cell cycle arrest, thereby having antitumor and antiviral effects. Senescent PrECs displayed elevated levels of IFN regulatory factor 3 mRNA. IFN regulatory factor 3 transactivates IFN-responsive genes through sequence specific binding of IFN response elements (51). IFN-α-inducible protein IFI-6-16 was dramatically increased in senescent PrECs as determined by MicroSAGE and qPCR analysis (Fig. 2 A). Furthermore, IFN-induced transmembrane protein 2 (1–8D) was induced in senescent PrECs. Although the function of these genes is unknown, their induction could be involved in the dominant cell cycle arrest observed in senescent PrECs.

Senescent PrECs showed increased connexin 26 expression. Connexin 26 protein forms intercellular channels present in gap junctions, which allow the transfer of ions and small signaling molecules between basal and luminal cells of the human prostate (52). Consistent with a role of connexin 26 in regulation of cell proliferation and differentiation, prostate cancer cell growth can be suppressed by ectopic expression of connexin 26(53).

Apoptosis.

Senescent cells acquire an increased resistance towards apoptotic insults (54, 55). In senescent PrECs, this may, in part, be because of the down-regulation of the proapoptotic gene Bad detected in this study (Table 2). On the other hand, we observed induction of TRAIL (APO2L, confirmed by qPCR, Fig. 2), which binds to the TRAIL receptors TRAILR1/DR4 and TRAILR2/DR5 (56). TRAIL induces apoptosis in prostate cancer cells but also in normal PrECs (57). It will be interesting to determine whether increased TRAIL expression, which may occur in the prostate because of accumulation of senescent PrECs (17), contributes to suppression of tumor formation in the aging prostate.

In the future, it will be important to analyze whether the differential regulation of genes identified in this study is required for the induction or maintenance of senescence in PrECs. During neoplastic transformation, genes required for the senescent phenotype may be inactivated through genetic (mutation, deletion) or epigenetic alterations (e.g., methylation). Furthermore, transcriptional repression of senescence-inducing genes may occur. Therefore, genome-wide analyses of changes in gene expression patterns and of genetic alterations, which occur during formation of prostate cancer, will be complementary to this study. Recent examples of gene expressing studies on prostate cancer cells (25, 58, 59, 60) include a report by Shou et al. (60), which shows that down-regulation of several IFN-regulated genes is characteristic for the transition from nontumorigenic benign prostatic hyperplasia to tumorigenic prostatic hyperplasia: one of these genes is IFI-6-16, which is strongly induced during senescence (Table 1, Fig. 2). These examples suggest that genes induced during senescence are good candidates for genes, which are inactivated/down-regulated during cancer initiation and/or progression. On the other hand, genes down-regulated during cellular senescence may represent potential therapeutic targets for inhibition of prostate cancer cell proliferation because specific inhibition of such gene products may lead to reactivation of the senescence program in immortal cancer cells.

Fig. 1.

Senescence of human PrECs. PrECs were cultivated in collagen type I-treated flasks. Cells were passaged by splitting in a 1:3 ratio until the population ceased to expand (passage 10, ∼30 population doublings). a, morphology of PrECs during cultivation. Phase contrast images of early passage (left panel) and late passage cells (right panel, ×100 magnification). b, protein levels of cdk inhibitors and p53. Protein extracts were prepared from ∼70% confluent cells of passage 5–8 and subjected to Western blot analysis. See “Materials and Methods” for details. Total protein (50 μg) was loaded. α-Tubulin served as loading and transfer control. c, qPCR analysis of gene expression in senescent PrECs. The results shown correspond to the average of four measurements. For details, see “Materials and Methods.”

Fig. 1.

Senescence of human PrECs. PrECs were cultivated in collagen type I-treated flasks. Cells were passaged by splitting in a 1:3 ratio until the population ceased to expand (passage 10, ∼30 population doublings). a, morphology of PrECs during cultivation. Phase contrast images of early passage (left panel) and late passage cells (right panel, ×100 magnification). b, protein levels of cdk inhibitors and p53. Protein extracts were prepared from ∼70% confluent cells of passage 5–8 and subjected to Western blot analysis. See “Materials and Methods” for details. Total protein (50 μg) was loaded. α-Tubulin served as loading and transfer control. c, qPCR analysis of gene expression in senescent PrECs. The results shown correspond to the average of four measurements. For details, see “Materials and Methods.”

Close modal
Fig. 2.

Confirmation of tag-to-gene assignments and reproducibility in PrECs samples from three different donors using quantitative PCR. Fold induction/repression indicates the differences in expression between confluent, early passage (2.–3.) and senescent, late passage (10.–12.) PrECs. The numbers of corresponding SAGE-tags in the respective libraries (confluent:senescent) are indicated below the gene symbol. qPCR analysis was performed on cDNA derived from PrECs, which were also used for SAGE (PrEC-SAGE), and from two additional donors [PrEC1 (56 years old) and PrEC2 (63 years old)]. Each bar corresponds to the average of 2–4 measurements. For details, see “Materials and Methods.” a, transcripts induced during senescence of PrECs. b, transcripts repressed during senescence of PrECs. ACTB (31:26) served as an example of a transcript not altered in abundance.

Fig. 2.

Confirmation of tag-to-gene assignments and reproducibility in PrECs samples from three different donors using quantitative PCR. Fold induction/repression indicates the differences in expression between confluent, early passage (2.–3.) and senescent, late passage (10.–12.) PrECs. The numbers of corresponding SAGE-tags in the respective libraries (confluent:senescent) are indicated below the gene symbol. qPCR analysis was performed on cDNA derived from PrECs, which were also used for SAGE (PrEC-SAGE), and from two additional donors [PrEC1 (56 years old) and PrEC2 (63 years old)]. Each bar corresponds to the average of 2–4 measurements. For details, see “Materials and Methods.” a, transcripts induced during senescence of PrECs. b, transcripts repressed during senescence of PrECs. ACTB (31:26) served as an example of a transcript not altered in abundance.

Close modal

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1

Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org).

3

The abbreviations used are: Cdk, cyclin-dependent kinase; PrEC, prostate epithelial cell; SAGE, serial analysis of gene expression; qPCR, quantitative real-time PCR; ECM, extracellular matrix; TNF, tumor necrosis factor; TRAIL, TNF-related apoptosis-inducing ligand.

4

Internet address: www.sagenet.org.

5

Internet address: www.ncbi.nlm.nih.gov/SAGE/SAGEtag.cgi.

6

Internet address: www.cgap.nci.nih.gov/SAGE. Library designations: “SAGE_prostate_primary_B_senescent” and “SAGE_prostate_primary_B_confluent.”

7

H. Hermeking and A. Menssen, unpublished results.

Table 1

Functional classification of genes up-regulated during cellular senescence

Seventy significantly up-regulated tags are shown. The genes matching to these tags were assigned to functional classes. For some tags, the 11. base, which was retrieved using the SAGE2000 software, is indicated. The column “tag# con.” indicates the number of tags in the SAGE library derived from confluent, early passage PrECs, whereas the column labelled “tag# sen.” gives the tag abundance in the senescent PrECs derived library. P chance was obtained by Monte Carlo simulation. The right column indicates references of previously published expression data for the respective transcript, which shows a correlation to this study. A = SAGE analysis of normal prostate tissue and prostate tumor tissue obtained by manual microdissection of frozen tissue. These SAGE libraries are “SAGE_PR317_normal prostate” and “SAGE_PR317_prostate_tumor” accessible online.6

Functional class tag sequenceTag# con.Tag# sen.Fold ind.P chanceDescription (assigned mRNA)Unigene accession no.FunctionCorrelation with ref.
Cell cycle         
TCACAGCTGT 11 5.5 0.0124 B-cell translocation gene 1, antiproliferative Hs.77054 Cell cycle inhibition  
AAAGTCTAGA 0.0370 Cyclin D1 Hs.82932 Cell cycle regulation A, 25 
Extracellular matrix         
TAAAAATGTT 27 106 3.9 0.0000 Plasminogen activator inhibitor type 1, PAI-1 Hs.82085 ECM remodeling  28  
GGTTATTTTG 21 3.5 0.0030 Plasminogen activator inhibitor type 1, PAI-1 Hs.82085 ECM remodeling  28  
TGGGTGAGCC 23 61 2.6 0.0000 Cathepsin B Hs.297939 Protease  25  
ATCTTGTTAC >8 0.0037 Fibronectin 1 Hs.287820 Cell adhesion/shape  27  
GACCACCTTT 16 0.0056 Microfibrillar-associated protein 2 Hs.83551 Extracellular matrix  27  
TGTTAGAAAA 0.0370 Procollagen-lysine 2-oxoglutarate 5-dioxygenase 2 Hs.41270 Collagen biosynthesis  
GGGAGGGGTG G 15 2.5 0.0400 Matrix metalloproteinase 14, MMP-14 Hs.2399 Protease 28, 29 
AAGGGGGCAA 15 0.0203 β4 integrin Hs.85266 Cell-matrix contact  
Cellular shape and motility         
TCCAAATCGA 21 4.2 0.0013 Vimentin Hs.297753 Intermediate filament 
TTAAAGATTT 15 3.7 0.0101 Tropomyosin 1 α Hs.77899 Cytoskeleton 25, 26 
TGTAGAAAAA A 0.0106 β-tubulin Hs.336780 Microtubuli  
GACTGTGCCA 18 0.0122 Dynein, cytoplasmic Hs.5120 Intracellular transport  25  
TCACCGGTCA 0.0178 Gelsolin, cytoplasmic, and secreted Hs.290070 Actin fragmentation 
CGAATGTCCT 11 3.6 0.0301 Keratin 6B Hs.335952 Intermediate filament  
CAGCTGGCCC >6 0.0173 Fibulin 1 Hs.79732 Fibronectin-receptor bdg.  
GCTAAGGAGA 0.0178 RAC1, ras-related Hs.173737 Lamellipodia formation  
CCTTGCTTTT >6 0.0173 cdc42 Hs.146409 Filopodia formation  
Transcription         
CCTACCACCA >6 0.0173 NFKB (p65)-associated inhibitor Hs.324051 Transcriptional regulation  
CTGCCCCACA >6 0.0173 SKI (oncoprotein)-interacting protein, SKIP Hs.79008 DNA binding protein  
CACAGGCAAA 18 2.5 0.0235 Basic leucine-zipper protein BZAP45 Hs.155291 Transcription factor  
TTCCGGTTCC 16 2.6 0.0236 Nucleobindin 1 Hs.172609 DNA binding protein  
CCTTTCACAC 10 3.3 0.0483 General transcription factor TF II-i Hs.278589 INR binding protein  30  
Signaling         
CCCTCAGCAC 16 0.0006 Annexin A8 Hs.87268 Signal transduction  
ATGCTCCCTG A >8 0.0037 90K serum protein (lectin 3 binding protein) Hs.79339 Signal transduction  
TGCAATAGGG >5 0.0297 Protein phosphatase 1, regulatory subunit 12C Hs.235975 Signal transduction  
CTTTCTTTGA G 11 3.6 0.0301 Dickkopf 3, Dkk3 Hs.4909 wnt-signaling inhibition 
GGCCATCTCT 14 2.8 0.0323 14-3-3 tau Hs.74405 Signal transduction  
CACGCAATGC T 10 3.3 0.0483 Amino terminal enhancer of split, G-protein Hs.244 Signaling  
GTTTCCAAAA 20 3.3 0.0049 Gap junction protein, β 2, connexin 26 Hs.323733 Cell-cell channels  
Cytokine/growth factor         
GACGGCGCAG >5 0.0297 Endothelial cell growth factor 1, ECGF1 Hs.73946 Endothelial cell specific  
TAAAAATAAC 17 3.4 0.0082 Parathyroid-hormone related protein, PTHRP Hs.89626 Hormone  
CCACTACACT C 4.5 0.0323 TNF-related apoptosis-inducing ligand, TRAIL Hs.83429 Apoptosis induction  
IFN related         
CGCCGACGAT 36 0.0000 IFN α-inducible protein (IFI-6-16) Hs.265827 Unknown 
ACCATTCTGC 10 10 0.0055 IFN ind. transmembrane protein 2 (1–8D) Hs.174195 Unknown 
GTGTGCCTCC >7 0.0075 IFN regulatory factor 3, IRF3 Hs.75254 Transcription factor  
ACCTGTATCC 20 2.5 0.0176 IFN ind. transmembrane protein 3 (1-8U) Hs.182241 Unknown 
Intracellular transport         
GGGCCTGTGC C 29 3.2 0.0008 Solute carrier family 16, member 3, MCT3 Hs.85838 Lactate + pyruvate transp.  
TCATTTTCCA A 12 0.0066 Solute carrier family 6, member 8, CT1 Hs.187958 Creatin transporter  
TTCATTTGTC >5 0.0297 Solute carrier family 20, SLC20A1 Hs.78452 Phosphate transporter  
AGTGCAAAAT >7 0.0075 Ion transport regulator 3 Hs.301350 Transport  
GTGCAGGCTC >6 0.0173 TAP1 Hs.352018 MHC-I peptide ER-import  
TATTTATTGA A 10 0.0210 Coat protein γ-cop Hs.102950 Transport  
Metabolism         
TAGACCCCTT 10 3.3 0.0483 Glyceraldehyde-3-phosphate dehydrogenase Hs.169476 Glycolysis  
TCTTGTGCAT 23 2.5 0.0105 Lactate dehydrogenase A Hs.2795 Glycolysis  26  
GAAACAAGAT 14 48 3.4 0.0000 Phosphoglycerate kinase 1 Hs.78771 Glycolysis  
GGGAATAAAC 20 6.6 0.0003 Mevalonate (diphospho) decarboxylase Hs.3828 Cholesterol biosynthesis  
CGACCCCACG 14 0.0022 Apolipoprotein E Hs.169401 Lipid transport  
TGTATTCAGC 15 0.0037 Fatty acid desaturase 3 Hs.21765 Lipid metabolism  
GTGCGGAGGA 13 6.5 0.0038 Serum amyloid A1 Hs.332053 Associates w/HDL-prot.  
TTATGGCAGA 10 10 0.0055 ATP synthase, mit. F1 complex, ATP5E Hs.177530 ATP synthesis 
GGAACTTTTA 10 0.0210 Similar to glucosamine-6-sulfatases Hs.43857   
Protein synthesis         
GGGAAACCTT G 4.5 0.0323 Ribosomal protein S6 Hs.241507 Protein synthesis  
TAAATATAAA >5 0.0297 Mitochondrial, ribosomal protein L18 Hs.23038 Protein synthesis  
TGGTGCAGCA >8 0.0037 Mitochondrial, ribosomal protein S7 Hs.71787 Protein synthesis  
TCTGCAAGAA >6 0.0173 Mitochondrial, ribosomal protein S21 Hs.81281 Protein synthesis  
AACTCTTGAA 13 3.2 0.0244 Translation initiation factor 3, s.u. 3 γ Hs.58189 Protein synthesis A, 30 
TAAATAATAC 0.0370 KIAA0111 gene product, initiation factor 4A-like Hs.79768 Protein synthesis  
TACAAAACCA 0.0370 Nucleolin Hs.79110 Ribosome synthesis  
TGCACCACAG 13 3.2 0.0244 Microsomal signal peptidase (18kD) Hs.9534 Protease  
Other functions         
TGCAATGACT 34 170 0.0000 S100 calcium-binding protein A2 Hs.38991 Stress response  
AAGCAGAAGG 15 >15 0.0000 S100 calcium-binding protein A10, p11 Hs.119301 Stress response  
GTGCTGGACC T 0.0178 Proteasome activator subunit 2 (PA28-β) Hs.179774 Protein degradation  
TGGCTTAAAT G 10 0.0210 Hypoxia-inducible protein 2 Hs.61762 Unknown  
TTTTTGTATT 10 0.0210 Thioredoxin interacting protein Hs.179526 Unknown 
AACATAGGAA 0.0370 CD59 antigen p18–20 Hs.278573 Cell surface protein  
TACATTTGGA C 0.0370 CAAX box 1 Hs.250708 Membrane protein  
ATCATTCCCT 10 3.3 0.0483 dpy-30-like protein Hs.323401 Differentiation  
GAGGCCATCC 15 2.5 0.0400 U6 snRNA-associated Sm-like protein LSm7 Hs.70830 RNA processing  25  
Functional class tag sequenceTag# con.Tag# sen.Fold ind.P chanceDescription (assigned mRNA)Unigene accession no.FunctionCorrelation with ref.
Cell cycle         
TCACAGCTGT 11 5.5 0.0124 B-cell translocation gene 1, antiproliferative Hs.77054 Cell cycle inhibition  
AAAGTCTAGA 0.0370 Cyclin D1 Hs.82932 Cell cycle regulation A, 25 
Extracellular matrix         
TAAAAATGTT 27 106 3.9 0.0000 Plasminogen activator inhibitor type 1, PAI-1 Hs.82085 ECM remodeling  28  
GGTTATTTTG 21 3.5 0.0030 Plasminogen activator inhibitor type 1, PAI-1 Hs.82085 ECM remodeling  28  
TGGGTGAGCC 23 61 2.6 0.0000 Cathepsin B Hs.297939 Protease  25  
ATCTTGTTAC >8 0.0037 Fibronectin 1 Hs.287820 Cell adhesion/shape  27  
GACCACCTTT 16 0.0056 Microfibrillar-associated protein 2 Hs.83551 Extracellular matrix  27  
TGTTAGAAAA 0.0370 Procollagen-lysine 2-oxoglutarate 5-dioxygenase 2 Hs.41270 Collagen biosynthesis  
GGGAGGGGTG G 15 2.5 0.0400 Matrix metalloproteinase 14, MMP-14 Hs.2399 Protease 28, 29 
AAGGGGGCAA 15 0.0203 β4 integrin Hs.85266 Cell-matrix contact  
Cellular shape and motility         
TCCAAATCGA 21 4.2 0.0013 Vimentin Hs.297753 Intermediate filament 
TTAAAGATTT 15 3.7 0.0101 Tropomyosin 1 α Hs.77899 Cytoskeleton 25, 26 
TGTAGAAAAA A 0.0106 β-tubulin Hs.336780 Microtubuli  
GACTGTGCCA 18 0.0122 Dynein, cytoplasmic Hs.5120 Intracellular transport  25  
TCACCGGTCA 0.0178 Gelsolin, cytoplasmic, and secreted Hs.290070 Actin fragmentation 
CGAATGTCCT 11 3.6 0.0301 Keratin 6B Hs.335952 Intermediate filament  
CAGCTGGCCC >6 0.0173 Fibulin 1 Hs.79732 Fibronectin-receptor bdg.  
GCTAAGGAGA 0.0178 RAC1, ras-related Hs.173737 Lamellipodia formation  
CCTTGCTTTT >6 0.0173 cdc42 Hs.146409 Filopodia formation  
Transcription         
CCTACCACCA >6 0.0173 NFKB (p65)-associated inhibitor Hs.324051 Transcriptional regulation  
CTGCCCCACA >6 0.0173 SKI (oncoprotein)-interacting protein, SKIP Hs.79008 DNA binding protein  
CACAGGCAAA 18 2.5 0.0235 Basic leucine-zipper protein BZAP45 Hs.155291 Transcription factor  
TTCCGGTTCC 16 2.6 0.0236 Nucleobindin 1 Hs.172609 DNA binding protein  
CCTTTCACAC 10 3.3 0.0483 General transcription factor TF II-i Hs.278589 INR binding protein  30  
Signaling         
CCCTCAGCAC 16 0.0006 Annexin A8 Hs.87268 Signal transduction  
ATGCTCCCTG A >8 0.0037 90K serum protein (lectin 3 binding protein) Hs.79339 Signal transduction  
TGCAATAGGG >5 0.0297 Protein phosphatase 1, regulatory subunit 12C Hs.235975 Signal transduction  
CTTTCTTTGA G 11 3.6 0.0301 Dickkopf 3, Dkk3 Hs.4909 wnt-signaling inhibition 
GGCCATCTCT 14 2.8 0.0323 14-3-3 tau Hs.74405 Signal transduction  
CACGCAATGC T 10 3.3 0.0483 Amino terminal enhancer of split, G-protein Hs.244 Signaling  
GTTTCCAAAA 20 3.3 0.0049 Gap junction protein, β 2, connexin 26 Hs.323733 Cell-cell channels  
Cytokine/growth factor         
GACGGCGCAG >5 0.0297 Endothelial cell growth factor 1, ECGF1 Hs.73946 Endothelial cell specific  
TAAAAATAAC 17 3.4 0.0082 Parathyroid-hormone related protein, PTHRP Hs.89626 Hormone  
CCACTACACT C 4.5 0.0323 TNF-related apoptosis-inducing ligand, TRAIL Hs.83429 Apoptosis induction  
IFN related         
CGCCGACGAT 36 0.0000 IFN α-inducible protein (IFI-6-16) Hs.265827 Unknown 
ACCATTCTGC 10 10 0.0055 IFN ind. transmembrane protein 2 (1–8D) Hs.174195 Unknown 
GTGTGCCTCC >7 0.0075 IFN regulatory factor 3, IRF3 Hs.75254 Transcription factor  
ACCTGTATCC 20 2.5 0.0176 IFN ind. transmembrane protein 3 (1-8U) Hs.182241 Unknown 
Intracellular transport         
GGGCCTGTGC C 29 3.2 0.0008 Solute carrier family 16, member 3, MCT3 Hs.85838 Lactate + pyruvate transp.  
TCATTTTCCA A 12 0.0066 Solute carrier family 6, member 8, CT1 Hs.187958 Creatin transporter  
TTCATTTGTC >5 0.0297 Solute carrier family 20, SLC20A1 Hs.78452 Phosphate transporter  
AGTGCAAAAT >7 0.0075 Ion transport regulator 3 Hs.301350 Transport  
GTGCAGGCTC >6 0.0173 TAP1 Hs.352018 MHC-I peptide ER-import  
TATTTATTGA A 10 0.0210 Coat protein γ-cop Hs.102950 Transport  
Metabolism         
TAGACCCCTT 10 3.3 0.0483 Glyceraldehyde-3-phosphate dehydrogenase Hs.169476 Glycolysis  
TCTTGTGCAT 23 2.5 0.0105 Lactate dehydrogenase A Hs.2795 Glycolysis  26  
GAAACAAGAT 14 48 3.4 0.0000 Phosphoglycerate kinase 1 Hs.78771 Glycolysis  
GGGAATAAAC 20 6.6 0.0003 Mevalonate (diphospho) decarboxylase Hs.3828 Cholesterol biosynthesis  
CGACCCCACG 14 0.0022 Apolipoprotein E Hs.169401 Lipid transport  
TGTATTCAGC 15 0.0037 Fatty acid desaturase 3 Hs.21765 Lipid metabolism  
GTGCGGAGGA 13 6.5 0.0038 Serum amyloid A1 Hs.332053 Associates w/HDL-prot.  
TTATGGCAGA 10 10 0.0055 ATP synthase, mit. F1 complex, ATP5E Hs.177530 ATP synthesis 
GGAACTTTTA 10 0.0210 Similar to glucosamine-6-sulfatases Hs.43857   
Protein synthesis         
GGGAAACCTT G 4.5 0.0323 Ribosomal protein S6 Hs.241507 Protein synthesis  
TAAATATAAA >5 0.0297 Mitochondrial, ribosomal protein L18 Hs.23038 Protein synthesis  
TGGTGCAGCA >8 0.0037 Mitochondrial, ribosomal protein S7 Hs.71787 Protein synthesis  
TCTGCAAGAA >6 0.0173 Mitochondrial, ribosomal protein S21 Hs.81281 Protein synthesis  
AACTCTTGAA 13 3.2 0.0244 Translation initiation factor 3, s.u. 3 γ Hs.58189 Protein synthesis A, 30 
TAAATAATAC 0.0370 KIAA0111 gene product, initiation factor 4A-like Hs.79768 Protein synthesis  
TACAAAACCA 0.0370 Nucleolin Hs.79110 Ribosome synthesis  
TGCACCACAG 13 3.2 0.0244 Microsomal signal peptidase (18kD) Hs.9534 Protease  
Other functions         
TGCAATGACT 34 170 0.0000 S100 calcium-binding protein A2 Hs.38991 Stress response  
AAGCAGAAGG 15 >15 0.0000 S100 calcium-binding protein A10, p11 Hs.119301 Stress response  
GTGCTGGACC T 0.0178 Proteasome activator subunit 2 (PA28-β) Hs.179774 Protein degradation  
TGGCTTAAAT G 10 0.0210 Hypoxia-inducible protein 2 Hs.61762 Unknown  
TTTTTGTATT 10 0.0210 Thioredoxin interacting protein Hs.179526 Unknown 
AACATAGGAA 0.0370 CD59 antigen p18–20 Hs.278573 Cell surface protein  
TACATTTGGA C 0.0370 CAAX box 1 Hs.250708 Membrane protein  
ATCATTCCCT 10 3.3 0.0483 dpy-30-like protein Hs.323401 Differentiation  
GAGGCCATCC 15 2.5 0.0400 U6 snRNA-associated Sm-like protein LSm7 Hs.70830 RNA processing  25  
Table 2

Functional classification of genes repressed during cellular senescence

Sixty-five significantly repressed tags are depicted. The genes matching to these tags were assigned to functional classes. See legend of Table 1 for details.

Functional class tag sequenceTag# con.Tag# sen.Fold repr.P chanceDescription (assigned mRNA)Unigene accession no.FunctionCorrelation with ref.
Cell cycle related         
TTAAAAGCCT 37 4.1 0.0000 CDC28 protein kinase 1, CKS-1 Hs.77550 cdk regulation 27, 28, 29 
TGCCATCTGT 11 5.5 0.0119 Cyclin B1 Hs.23960 G2-M regulation A, 28, 29 
CCTAAGGCTA 4.5 0.0374 E2F4 Hs.108371 Transcription factor  25  
CGTTCCTGCG 24 3.4 0.0017 Inhibitor of DNA binding 1, Id1 Hs.75424 Transcription factor 
Transcription         
GGATATGTGG 18 0.0008 Early growth response 1, EGR1 Hs.326035 Transcription factor 
ACAGTGGGGA 15 0.0200 Unactive progesterone receptor (23 kD), ZNF6 Hs.278270 Transcription factor A, 30 
ATCCCTCAGT 11 3.6 0.0310 ATF4, CREB2 Hs.181243 Transcriptional repressor  
GCTGGTCTGA >5 0.0319 HCNGP Hs.27299 Transcription factor  
TGGGGATTAC 13 4.3 0.0111 RNA polymerase I subunit, RPA12 Hs.57813 RNA Pol I transcription 
CTCTGAGAGA 4.5 0.0374 TF IIIA, GTF3A Hs.75113 5S RNA Pol I transcr. 
GACACTACAC 17 5.6 0.0013 p8 protein (candidate of metastasis 1), mitogenic Hs.8603 HLH DNA-binding factor  
TTGAAGGGCC 10 10 0.0058 TSC22-related leucin zipper protein Hs.75450 Transcriptional regulator  
Signaling         
TGCATTAACT 0.0184 Cyclic AMP phosphoprotein, 19 kD Hs.7351 Signal transduction  
TTCTCTCTGT 0.0184 ADP-ribosylation factor 5, ARF5 Hs.77541 GTP binding protein  
ATCTTTCTGG 11 3.6 0.0310 14-3-3ζ Hs.75103 Signal transduction  
TACCTCTGAT 33 3.6 0.0002 S100 calcium-binding protein P Hs.2962 Signal transduction  27  
Cytokine/growth factor         
GTATACCTAC >5 0.0319 Platelet-derived growth factor α, PDGFα Hs.37040 Growth factor  
GGGGCTGTAT 15 2.5 0.0401 Transforming growth factor β 1, TGF-β Hs.1103 Growth factor  
Cytoskeleton         
CATTAAATTC 15 0.0037 Cytoskeleton-associated protein 1 Hs.31053 Cytoskeleton  
GCCGATCCTC 13 4.3 0.0111 α-Tubulin-specific chaperone Hs.24930 Protein folding  
Intracellular transport         
ATGATGATGA 35 14 2.5 0.0019 Mitochondrial adenine translocator 2, ANT2 Hs.79172 ADP/ATP translocase  
TTTCTAGTTT 22 2.7 0.0076 Transmembrane 4 α protein, lysosomal Hs.111894 Transporter  
DNA replication         
TGCAGCGCCT 62 20 3.1 0.0000 Uridine phosphorylase Hs.77573 Nucleoside synthesis  27  
GGCGTGAACC >5 0.0319 Proliferating cell nuclear antigen, PCNA Hs.78996 DNA-replication 28, 29 
Metabolism         
TAATGGTAAC 70 28 2.5 0.0000 Cytochrome c oxidase subunit Va Hs.181028 Respiratory chain 
GCCGCCATCT 20 6.6 0.0003 Transketolase (Wernicke-Korsakoff syndrome) Hs.89643 Metabolic enzyme  25  
GGCCCAGGCC >9 0.0020 Aldehyde dehydrogenase 3 family, member A1 Hs.575 Alcohol metabolism  
TCCTGAAAAA A 0.0106 Spermidine/spermine N1-acetyl transferase Hs.10846 Metabolic enzyme  
TTGGGGAAAC 19 2.7 0.0149 Biliverdin reductase A Hs.81029 Metabolic enzyme  
ATGCAGCCAT 14 3.5 0.0150 Ornithine decarboxylase 1, ODC1 Hs.75212 Polyamine biosynth. 
CGGCTGAATT 14 3.5 0.0150 Phosphogluconate dehydrogenase Hs.75888 Metabolic enzyme 
GCTTAACCTG 0.0184 Glutamate dehydrogenase 1 Hs.77508 Nitrogen-metabolism A, 25 
TGTACTTCCT >5 0.0319 Ornithine aminotransferase Hs.75485 Metabolic enzyme  
TGTGTTGTCA 0.0328 Methylene tetrahydrofolate dehydrogenase Hs.154672 Metabolic enzyme  
CCGTGCTCAT 4.5 0.0374 Carbonyl reductase Hs.9857 Metabolic enzyme 
TTTGGAAAAA 10 3.3 0.0468 Glyceronephosphate O-acyltransferase Hs.12482 Phospholipid biosynthesis  
TAAAGACTTG >5 0.0319 Adenylate kinase 2 Hs.171811 ATP-ADP cycle  
RNA processing         
TTGATGTACA 4.5 0.0374 Splicing factor 11, SFRS11 Hs.11482 RNA processing  
CGTGTTAATG 15 2.5 0.0401 ZNF9 (myotonic dystophy 2) Hs.2110 RNA binding  
TCCTAGCCTG >6 0.0171 Splicing factor similar to DnaJ Hs.74711 RNA splicing  
Protein synthesis         
TTGGCGGGTC 15 2.5 0.0401 Ribosomal protein S17 Hs.5174 Protein synthesis  
GAAGCCAGCC 14 3.5 0.0150 Translation initiation factor 4E bdg. prot. 1 Hs.71819 Protein synthesis inhibitor  
TCATCTTTGT >5 0.0319 Mitochondrial ribosomal protein L3 Hs.79086 Protein synthesis 
GCCCAGCGGC C 10 0.0184 Mitochondrial ribosomal protein L4 Hs.279652 Protein synthesis 
Protein degradation         
TAATTTGATT >8 0.0042 Ubiquitin-conjugating enzyme E2G 1 Hs.78563 Protein degradation  
CAGCCAAATA 10 10 0.0058 F-box protein FBX30 Hs.321687 Ubiquitination  25  
GGCTCGGGAT >5 0.0319 Calpain 1, (mu/l) large subunit Hs.2575 Protease  
Other functions         
CTGCTAAAAG C 17 4.2 0.0035 Cystatin A (stefin A) Hs.2621 Proteinase inhibitor  
GGAGCTGGCC 23 2.9 0.0052 Artemin Hs.194689 Neurotrophic factor  
TTTGGGGCTG 15 3.7 0.0104 ATPase, H+ pump, lysosomal, 21kD Hs.7476 Acidification A, 25 
GGGTGCTTGG >5 0.0319 ATPase, H+ pump, lysosomal, subunit 1 Hs.6551 Acidification of organelles  
GGAGCCATTC 0.0328 ATPase, H+ transp. lysosomal, member M Hs.272630 Acidification of organelles  
GATTACCTGT 0.0106 Hexosaminidase A (alpha polypeptide) Hs.119403 Ganglioside catabolism  
GAGGCGCTGG G 12 0.0179 BAD Hs.76366 Apoptosis regulation 
GCGGGAGGGC 10 0.0184 ADP-ribosylation factor-like 2 Hs.154162 GTP binding protein  
CCCTATCACA >5 0.0319 CATX-8 protein, ras-related Hs.150826 GTP binding protein  
GGGCCTGGGG A 10 0.0184 Epsin Hs.279953 Endocytosis  25  
TAAGTTTAAT 10 0.0184 Sterol carrier protein 2, intracellular Hs.75760 Cholesterol transporter  
CTGGCCCGGA G 15 0.0200 Vasodilator-stimulated phosphoprotein, VASP Hs.93183 Focal adhesion stability  
TTTGGAATGT 13 3.2 0.0249 Matrin 3 Hs.78825 Nuclear matrix  
GCAGGGCCAG G >5 0.0319 XRCC1 Hs.98493 DNA-repair  
CTTTTCAAGA A 0.0328 Membrane cofactor protein (CD46) Hs.83532 Measles virus receptor  
TGGGCTCTGA A 10 3.3 0.0468 CD36L2, lysosomal Hs.323567 Receptor 
CCCCCACCTA 4.5 0.0374 Proteolipid protein 2 Hs.77422 Unknown  
CAAATGAGGA 0.0328 Gene upstream of NRAS, UNR Hs.69855 Unknown  
Functional class tag sequenceTag# con.Tag# sen.Fold repr.P chanceDescription (assigned mRNA)Unigene accession no.FunctionCorrelation with ref.
Cell cycle related         
TTAAAAGCCT 37 4.1 0.0000 CDC28 protein kinase 1, CKS-1 Hs.77550 cdk regulation 27, 28, 29 
TGCCATCTGT 11 5.5 0.0119 Cyclin B1 Hs.23960 G2-M regulation A, 28, 29 
CCTAAGGCTA 4.5 0.0374 E2F4 Hs.108371 Transcription factor  25  
CGTTCCTGCG 24 3.4 0.0017 Inhibitor of DNA binding 1, Id1 Hs.75424 Transcription factor 
Transcription         
GGATATGTGG 18 0.0008 Early growth response 1, EGR1 Hs.326035 Transcription factor 
ACAGTGGGGA 15 0.0200 Unactive progesterone receptor (23 kD), ZNF6 Hs.278270 Transcription factor A, 30 
ATCCCTCAGT 11 3.6 0.0310 ATF4, CREB2 Hs.181243 Transcriptional repressor  
GCTGGTCTGA >5 0.0319 HCNGP Hs.27299 Transcription factor  
TGGGGATTAC 13 4.3 0.0111 RNA polymerase I subunit, RPA12 Hs.57813 RNA Pol I transcription 
CTCTGAGAGA 4.5 0.0374 TF IIIA, GTF3A Hs.75113 5S RNA Pol I transcr. 
GACACTACAC 17 5.6 0.0013 p8 protein (candidate of metastasis 1), mitogenic Hs.8603 HLH DNA-binding factor  
TTGAAGGGCC 10 10 0.0058 TSC22-related leucin zipper protein Hs.75450 Transcriptional regulator  
Signaling         
TGCATTAACT 0.0184 Cyclic AMP phosphoprotein, 19 kD Hs.7351 Signal transduction  
TTCTCTCTGT 0.0184 ADP-ribosylation factor 5, ARF5 Hs.77541 GTP binding protein  
ATCTTTCTGG 11 3.6 0.0310 14-3-3ζ Hs.75103 Signal transduction  
TACCTCTGAT 33 3.6 0.0002 S100 calcium-binding protein P Hs.2962 Signal transduction  27  
Cytokine/growth factor         
GTATACCTAC >5 0.0319 Platelet-derived growth factor α, PDGFα Hs.37040 Growth factor  
GGGGCTGTAT 15 2.5 0.0401 Transforming growth factor β 1, TGF-β Hs.1103 Growth factor  
Cytoskeleton         
CATTAAATTC 15 0.0037 Cytoskeleton-associated protein 1 Hs.31053 Cytoskeleton  
GCCGATCCTC 13 4.3 0.0111 α-Tubulin-specific chaperone Hs.24930 Protein folding  
Intracellular transport         
ATGATGATGA 35 14 2.5 0.0019 Mitochondrial adenine translocator 2, ANT2 Hs.79172 ADP/ATP translocase  
TTTCTAGTTT 22 2.7 0.0076 Transmembrane 4 α protein, lysosomal Hs.111894 Transporter  
DNA replication         
TGCAGCGCCT 62 20 3.1 0.0000 Uridine phosphorylase Hs.77573 Nucleoside synthesis  27  
GGCGTGAACC >5 0.0319 Proliferating cell nuclear antigen, PCNA Hs.78996 DNA-replication 28, 29 
Metabolism         
TAATGGTAAC 70 28 2.5 0.0000 Cytochrome c oxidase subunit Va Hs.181028 Respiratory chain 
GCCGCCATCT 20 6.6 0.0003 Transketolase (Wernicke-Korsakoff syndrome) Hs.89643 Metabolic enzyme  25  
GGCCCAGGCC >9 0.0020 Aldehyde dehydrogenase 3 family, member A1 Hs.575 Alcohol metabolism  
TCCTGAAAAA A 0.0106 Spermidine/spermine N1-acetyl transferase Hs.10846 Metabolic enzyme  
TTGGGGAAAC 19 2.7 0.0149 Biliverdin reductase A Hs.81029 Metabolic enzyme  
ATGCAGCCAT 14 3.5 0.0150 Ornithine decarboxylase 1, ODC1 Hs.75212 Polyamine biosynth. 
CGGCTGAATT 14 3.5 0.0150 Phosphogluconate dehydrogenase Hs.75888 Metabolic enzyme 
GCTTAACCTG 0.0184 Glutamate dehydrogenase 1 Hs.77508 Nitrogen-metabolism A, 25 
TGTACTTCCT >5 0.0319 Ornithine aminotransferase Hs.75485 Metabolic enzyme  
TGTGTTGTCA 0.0328 Methylene tetrahydrofolate dehydrogenase Hs.154672 Metabolic enzyme  
CCGTGCTCAT 4.5 0.0374 Carbonyl reductase Hs.9857 Metabolic enzyme 
TTTGGAAAAA 10 3.3 0.0468 Glyceronephosphate O-acyltransferase Hs.12482 Phospholipid biosynthesis  
TAAAGACTTG >5 0.0319 Adenylate kinase 2 Hs.171811 ATP-ADP cycle  
RNA processing         
TTGATGTACA 4.5 0.0374 Splicing factor 11, SFRS11 Hs.11482 RNA processing  
CGTGTTAATG 15 2.5 0.0401 ZNF9 (myotonic dystophy 2) Hs.2110 RNA binding  
TCCTAGCCTG >6 0.0171 Splicing factor similar to DnaJ Hs.74711 RNA splicing  
Protein synthesis         
TTGGCGGGTC 15 2.5 0.0401 Ribosomal protein S17 Hs.5174 Protein synthesis  
GAAGCCAGCC 14 3.5 0.0150 Translation initiation factor 4E bdg. prot. 1 Hs.71819 Protein synthesis inhibitor  
TCATCTTTGT >5 0.0319 Mitochondrial ribosomal protein L3 Hs.79086 Protein synthesis 
GCCCAGCGGC C 10 0.0184 Mitochondrial ribosomal protein L4 Hs.279652 Protein synthesis 
Protein degradation         
TAATTTGATT >8 0.0042 Ubiquitin-conjugating enzyme E2G 1 Hs.78563 Protein degradation  
CAGCCAAATA 10 10 0.0058 F-box protein FBX30 Hs.321687 Ubiquitination  25  
GGCTCGGGAT >5 0.0319 Calpain 1, (mu/l) large subunit Hs.2575 Protease  
Other functions         
CTGCTAAAAG C 17 4.2 0.0035 Cystatin A (stefin A) Hs.2621 Proteinase inhibitor  
GGAGCTGGCC 23 2.9 0.0052 Artemin Hs.194689 Neurotrophic factor  
TTTGGGGCTG 15 3.7 0.0104 ATPase, H+ pump, lysosomal, 21kD Hs.7476 Acidification A, 25 
GGGTGCTTGG >5 0.0319 ATPase, H+ pump, lysosomal, subunit 1 Hs.6551 Acidification of organelles  
GGAGCCATTC 0.0328 ATPase, H+ transp. lysosomal, member M Hs.272630 Acidification of organelles  
GATTACCTGT 0.0106 Hexosaminidase A (alpha polypeptide) Hs.119403 Ganglioside catabolism  
GAGGCGCTGG G 12 0.0179 BAD Hs.76366 Apoptosis regulation 
GCGGGAGGGC 10 0.0184 ADP-ribosylation factor-like 2 Hs.154162 GTP binding protein  
CCCTATCACA >5 0.0319 CATX-8 protein, ras-related Hs.150826 GTP binding protein  
GGGCCTGGGG A 10 0.0184 Epsin Hs.279953 Endocytosis  25  
TAAGTTTAAT 10 0.0184 Sterol carrier protein 2, intracellular Hs.75760 Cholesterol transporter  
CTGGCCCGGA G 15 0.0200 Vasodilator-stimulated phosphoprotein, VASP Hs.93183 Focal adhesion stability  
TTTGGAATGT 13 3.2 0.0249 Matrin 3 Hs.78825 Nuclear matrix  
GCAGGGCCAG G >5 0.0319 XRCC1 Hs.98493 DNA-repair  
CTTTTCAAGA A 0.0328 Membrane cofactor protein (CD46) Hs.83532 Measles virus receptor  
TGGGCTCTGA A 10 3.3 0.0468 CD36L2, lysosomal Hs.323567 Receptor 
CCCCCACCTA 4.5 0.0374 Proteolipid protein 2 Hs.77422 Unknown  
CAAATGAGGA 0.0328 Gene upstream of NRAS, UNR Hs.69855 Unknown  

We thank Peter Palm for help with, and Dieter Oesterhelt for access to, automated sequencing, and Holger Rumpold and members of the lab for discussion and comments. Heiko Hermeking’s laboratory is supported by the Max-Planck-Society and the Deutsche Krebshilfe.

1
Hayflick L. The limited in vitro life time of human diploid cell strains.
Exp. Cell Res.
,
37
:
614
-636,  
1965
.
2
Campisi J. From cells to organisms: can we learn about aging from cells in culture?.
Exp. Gerontol.
,
36
:
607
-618,  
2001
.
3
Serrano M., Blasco M. A. Putting the stress on senescence.
Curr. Opin. Cell Biol.
,
13
:
748
-753,  
2001
.
4
Wright W. E., Shay J. W. Cellular senescence as a tumor-protection mechanism: the essential role of counting.
Curr. Opin. Genet. Dev.
,
11
:
98
-103,  
2001
.
5
Campisi J., Kim S. H., Lim C. S., Rubio M. Cellular senescence, cancer and aging: the telomere connection.
Exp. Gerontol.
,
36
:
1619
-1637,  
2001
.
6
Bringold F., Serrano M. Tumor suppressors and oncogenes in cellular senescence.
Exp. Gerontol.
,
35
:
317
-329,  
2000
.
7
Tyner S. D., Venkatachalam S., Choi J., Jones S., Ghebranious N., Igelmann H., Lu X., Soron G., Cooper B., Brayton C., Hee Park S., Thompson T., Karsenty G., Bradley A., Donehower L. A. p53 mutant mice that display early ageing-associated phenotypes.
Nature (Lond.)
,
415
:
45
-53,  
2002
.
8
Romanov S. R., Kozakiewicz B. K., Holst C. R., Stampfer M. R., Haupt L. M., Tlsty T. D. Normal human mammary epithelial cells spontaneously escape senescence and acquire genomic changes.
Nature (Lond.)
,
409
:
633
-637,  
2001
.
9
Morris J. A. The kinetics of epithelial cell generation: its relevance to cancer and ageing.
J. Theor. Biol.
,
199
:
87
-95,  
1999
.
10
Krtolica A., Parrinello S., Lockett S., Desprez P. Y., Campisi J. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging.
Proc. Natl. Acad. Sci. USA
,
98
:
12072
-12077,  
2001
.
11
Landis S. H., Murray T., Bolden S., Wingo P. A. Cancer statistics, 1999.
CA - Cancer J. Clin.
,
49
:
8
-31,  
1999
.
12
Coffey D. S. Prostate cancer. An overview of an increasing dilemma.
Cancer (Phila.)
,
71
:
880
-886,  
1993
.
13
Dong J. T., Isaacs W. B., Isaacs J. T. Molecular advances in prostate cancer.
Curr. Opin. Oncol.
,
9
:
101
-107,  
1997
.
14
Abate-Shen C., Shen M. M. Molecular genetics of prostate cancer.
Genes Dev.
,
14
:
2410
-2434,  
2000
.
15
Ruijter E., van de Kaa C., Miller G., Ruiter D., Debruyne F., Schalken J. Molecular genetics and epidemiology of prostate carcinoma.
Endocr. Rev.
,
20
:
22
-45,  
1999
.
16
Dimri G. P., Lee X., Basile G., Acosta M., Scott G., Roskelley C., Medrano E. E., Linskens M., Rubelj I., Pereira-Smith O., et al A biomarker that identifies senescent human cells in culture and in aging skin in vivo.
Proc. Natl. Acad. Sci. USA
,
92
:
9363
-9367,  
1995
.
17
Choi J., Shendrik I., Peacocke M., Peehl D., Buttyan R., Ikeguchi E. F., Katz A. E., Benson M. C. Expression of senescence-associated β-galactosidase in enlarged prostates from men with benign prostatic hyperplasia.
Urology
,
56
:
160
-166,  
2000
.
18
Velculescu V. E., Zhang L., Vogelstein B., Kinzler K. W. Serial analysis of gene expression.
Science (Wash. DC)
,
270
:
484
-487,  
1995
.
19
Menssen A., Hermeking H. Characterization of the c-MYC-regulated transcriptome by SAGE: identification and analysis of c-MYC target genes.
Proc. Natl. Acad. Sci. USA
,
99
:
6274
-6279,  
2002
.
20
Pfaffl M. W. A new mathematical model for relative quantification in real-time RT-PCR.
Nucleic Acids Res.
,
29
:
E45
2001
.
21
Lopez-Bermejo A., Buckway C. K., Devi G. R., Hwa V., Plymate S. R., Oh Y., Rosenfeld R. G. Characterization of insulin-like growth factor-binding protein-related proteins (IGFBP-rPs) 1, 2, and 3 in human prostate epithelial cells: potential roles for IGFBP-rP1 and 2 in senescence of the prostatic epithelium.
Endocrinology
,
141
:
4072
-4080,  
2000
.
22
Jarrard D. F., Sarkar S., Shi Y., Yeager T. R., Magrane G., Kinoshita H., Nassif N., Meisner L., Newton M. A., Waldman F. M., Reznikoff C. A. p16/pRb pathway alterations are required for bypassing senescence in human prostate epithelial cells.
Cancer Res.
,
59
:
2957
-2964,  
1999
.
23
Sandhu C., Peehl D. M., Slingerland J. p16INK4A mediates cyclin dependent kinase 4 and 6 inhibition in senescent prostatic epithelial cells.
Cancer Res.
,
60
:
2616
-2622,  
2000
.
24
Boon K., Osorio E. C., Greenhut S. F., Schaefer C. F., Shoemaker J., Polyak K., Morin P. J., Buetow K. H., Strausberg R. L., De Souza S. J., Riggins G. J. An anatomy of normal and malignant gene expression.
Proc. Natl. Acad. Sci. USA
,
99
:
11287
-11292,  
2002
.
25
Waghray A., Schober M., Feroze F., Yao F., Virgin J., Chen Y. Q. Identification of differentially expressed genes by serial analysis of gene expression in human prostate cancer.
Cancer Res.
,
61
:
4283
-4286,  
2001
.
26
Ahram M., Best C. J., Flaig M. J., Gillespie J. W., Leiva I. M., Chuaqui R. F., Zhou G., Shu H., Duray P. H., Linehan W. M., Raffeld M., Ornstein D. K., Zhao Y., Petricoin E. F., III, Emmert-Buck M. R. Proteomic analysis of human prostate cancer.
Mol. Carcinog.
,
33
:
9
-15,  
2002
.
27
Schwarze S. R., DePrimo S. E., Grabert L. M., Fu V. X., Brooks J. D., Jarrard D. F. Novel pathways associated with bypassing cellular senescence in human prostate epithelial cells.
J. Biol. Chem.
,
277
:
14877
-14883,  
2002
.
28
Shelton D. N., Chang E., Whittier P. S., Choi D., Funk W. D. Microarray analysis of replicative senescence.
Curr. Biol.
,
9
:
939
-945,  
1999
.
29
Ly D. H., Lockhart D. J., Lerner R. A., Schultz P. G. Mitotic misregulation and human aging.
Science (Wash. DC)
,
287
:
2486
-2492,  
2000
.
30
Welle S., Bhatt K., Thornton C. A. High-abundance mRNAs in human muscle: comparison between young and old.
J. Appl. Physiol.
,
89
:
297
-304,  
2000
.
31
Hara E., Uzman J. A., Dimri G. P., Nehlin J. O., Testori A., Campisi J. The helix-loop-helix protein Id-1 and a retinoblastoma protein binding mutant of SV40 T antigen synergize to reactivate DNA synthesis in senescent human fibroblasts.
Dev. Genet. (Amsterdam)
,
18
:
161
-172,  
1996
.
32
Ohtani N., Zebedee Z., Huot T. J., Stinson J. A., Sugimoto M., Ohashi Y., Sharrocks A. D., Peters G., Hara E. Opposing effects of Ets and Id proteins on p16INK4a expression during cellular senescence.
Nature (Lond.)
,
409
:
1067
-1070,  
2001
.
33
Weinberg R. A. E2F and cell proliferation: a world turned upside down.
Cell
,
85
:
457
-459,  
1996
.
34
Spruck C., Strohmaier H., Watson M., Smith A. P., Ryan A., Krek T. W., Reed S. I. A CDK-independent function of mammalian Cks1: targeting of SCF(Skp2) to the CDK inhibitor p27Kip1.
Mol. Cell
,
7
:
639
-650,  
2001
.
35
Wagner M., Hampel B., Hutter E., Pfister G., Krek W., Zwerschke W., Jansen-Durr P. Metabolic stabilization of p27 in senescent fibroblasts correlates with reduced expression of the F-box protein Skp2.
Exp. Gerontol.
,
37
:
41
-55,  
2001
.
36
West M. D., Shay J. W., Wright W. E., Linskens M. H. Altered expression of plasminogen activator and plasminogen activator inhibitor during cellular senescence.
Exp. Gerontol.
,
31
:
175
-193,  
1996
.
37
Vaheri A., Kurkinen M., Lehto V. P., Linder E., Timpl R. Codistribution of pericellular matrix proteins in cultured fibroblasts and loss in transformation: fibronectin and procollagen.
Proc. Natl. Acad. Sci. USA
,
75
:
4944
-4948,  
1978
.
38
Allen M. V., Smith G. J., Juliano R., Maygarden S. J., Mohler J. L. Down-regulation of the β4 integrin subunit in prostatic carcinoma and prostatic intraepithelial neoplasia.
Hum. Pathol.
,
29
:
311
-318,  
1998
.
39
Nishio K., Inoue A., Qiao S., Kondo H., Mimura A. Senescence and cytoskeleton: overproduction of vimentin induces senescent-like morphology in human fibroblasts.
Histochem. Cell Biol.
,
116
:
321
-327,  
2001
.
40
Dong Y., Asch H. L., Medina D., Ip C., Ip M., Guzman R., Asch B. B. Concurrent deregulation of gelsolin and cyclin D1 in the majority of human and rodent breast cancers.
Int. J. Cancer
,
81
:
930
-938,  
1999
.
41
Fujita H., Okada F., Hamada J., Hosokawa M., Moriuchi T., Koya R. C., Kuzumaki N. Gelsolin functions as a metastasis suppressor in B16-BL6 mouse melanoma cells and requirement of the carboxyl-terminus for its effect.
Int. J. Cancer
,
93
:
773
-780,  
2001
.
42
Horikawa I., Parker E. S., Solomon G. G., Barrett J. C. Up-regulation of the gene encoding a cytoplasmic dynein intermediate chain in senescent human cells.
J. Cell Biochem.
,
82
:
415
-421,  
2001
.
43
Wang F. L., Wang Y., Wong W. K., Liu Y., Addivinola F. J., Liang P., Chen L. B., Kantoff P. W., Pardee A. B. Two differentially expressed genes in normal human prostate tissue and in carcinoma.
Cancer Res.
,
56
:
3634
-3637,  
1996
.
44
Hayashido Y., Lucas A., Rougeot C., Godyna S., Argraves W. S., Rochefort H. Estradiol and fibulin-1 inhibit motility of human ovarian and breast cancer cells induced by fibronectin.
Int. J. Cancer
,
75
:
654
-658,  
1998
.
45
Nobes C. D., Hall A. Rho, rac, and cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia.
Cell
,
81
:
53
-62,  
1995
.
46
Liu C., Adamson E., Mercola D. Transcription factor EGR-1 suppresses the growth and transformation of human HT-1080 fibrosarcoma cells by induction of transforming growth factor β1.
Proc. Natl. Acad. Sci. USA
,
93
:
11831
-11836,  
1996
.
47
Ree A. H., Tvermyr M., Engebraaten O., Rooman M., Rosok O., Hovig E., Meza-Zepeda L. A., Bruland O. S., Fodstad O. Expression of a novel factor in human breast cancer cells with metastatic potential.
Cancer Res.
,
59
:
4675
-4680,  
1999
.
48
Vasseur S., Vidal Mallo G., Fiedler F., Bodeker H., Canepa E., Moreno S., Iovanna J. L. Cloning and expression of the human p8, a nuclear protein with mitogenic activity.
Eur. J. Biochem.
,
259
:
670
-675,  
1999
.
49
Dahl R., Wani B., Hayman M. J. The Ski oncoprotein interacts with Skip, the human homolog of Drosophila Bx42.
Oncogene
,
16
:
1579
-1586,  
1998
.
50
Tsuji T., Nozaki I., Miyazaki M., Sakaguchi M., Pu H., Hamazaki Y., Iijima O., Namba M. Antiproliferative activity of REIC/Dkk-3 and its significant down-regulation in non-small cell lung carcinomas.
Biochem. Biophys. Res. Commun.
,
289
:
257
-263,  
2001
.
51
Au W. C., Moore P. A., Lowther W., Juang Y. T., Pitha P. M. Identification of a member of the interferon regulatory factor family that binds to the interferon-stimulated response element and activates expression of interferon-induced genes.
Proc. Natl. Acad. Sci. USA
,
92
:
11657
-11661,  
1995
.
52
El-Alfy M., Pelletier G., Hermo L. S., Labrie F. Unique features of the basal cells of human prostate epithelium.
Microsc. Res. Tech.
,
51
:
436
-446,  
2000
.
53
Mehta P. P., Perez-Stable C., Nadji M., Mian M., Asotra K., Roos B. A. Suppression of human prostate cancer cell growth by forced expression of connexin genes.
Dev. Genet. (Amsterdam)
,
24
:
91
-110,  
1999
.
54
Banerjee S., Banerjee P. P., Brown T. R. Castration-induced apoptotic cell death in the Brown Norway rat prostate decreases as a function of age.
Endocrinology
,
141
:
821
-832,  
2000
.
55
Suh Y., Lee K. A., Kim W. H., Han B. G., Vijg J., Park S. C. Aging alters the apoptotic response to genotoxic stress.
Nat. Med.
,
8
:
3
-4,  
2002
.
56
Pan G., Ni J., Wei Y. F., Yu G., Gentz R., Dixit V. M. An antagonist decoy receptor and a death domain-containing receptor for TRAIL.
Science (Wash. DC)
,
277
:
815
-818,  
1997
.
57
Nesterov A., Ivashchenko Y., Kraft A. S. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) triggers apoptosis in normal prostate epithelial cells.
Oncogene
,
21
:
1135
-1140,  
2002
.
58
Luo J., Duggan D. J., Chen Y., Sauvageot J., Ewing C. M., Bittner M. L., Trent J. M., Isaacs W. B. Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling.
Cancer Res.
,
61
:
4683
-4688,  
2001
.
59
Mousses S., Bubendorf L., Wagner U., Hostetter G., Kononen J., Cornelison R., Goldberger N., Elkahloun A. G., Willi N., Koivisto P., Ferhle W., Raffeld M., Sauter G., Kallioniemi O. P. Clinical validation of candidate genes associated with prostate cancer progression in the CWR22 model system using tissue microarrays.
Cancer Res.
,
62
:
1256
-1260,  
2002
.
60
Shou J., Soriano R., Hayward S. W., Cunha G. R., Williams P. M., Gao W. Q. Expression profiling of a human cell line model of prostatic cancer reveals a direct involvement of interferon signaling in prostate tumor progression.
Proc. Natl. Acad. Sci. USA
,
99
:
2830
-2835,  
2002
.